Abstract

The purpose of this randomized trial was to measure the effect of intravenously administered tranexamic acid (TXA) on intraoperative blood loss (IOB) in patients undergoing bimaxillary orthognathic surgery (OS). The authors designed and implemented a double-blinded placebo-controlled trial composed of patients eligible for OS at the Hospital of South West Denmark (Esbjerg, Denmark) from August 2014 through September 2016. The primary predictor variable was a single intravenous dose of TXA 1g administered preoperatively or an equivalent saline placebo. The primary outcome was IOB determined by milliliters of blood in the suction canister and gauzes deducted from the volume of saline used intraoperatively. The study population consisted of 96 patients. The TXA group (n=51) and the placebo group (n=45) showed a median IOB of 275 and 403mL(P=.005), respectively. A significant effect of TXA was detected in women (median IOB, 153mL [96 to 233mL] in TXA group vs 329mL [185 to 582mL] in placebo group; P<.001), whereas no significant effect of TXA on IOB was detected in men (median IOB, 367mL [275 to 472mL] in TXA group vs 429mL [275 to 655mL] in placebo group; P=.23). No correlations were found between IOB and procedure length, procedure type, or hematologic markers (platelets, hemoglobin, and hematocrit). In contrast to other studies, this double-blinded randomized controlled trial found a hemostatic effect of TXA in women and none in men who underwent bimaxillary OS. To focus on the specific effect of TXA in men, future studies should include larger male samples.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.